Current management of inflammatory bowel disease

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• The etiology of ulcerative colitis and Crohn's disease remains unknown.
• Current treatments focus on pathogenetic mechanisms, including corticosteroids, sulphasalazine, immunosuppressants (azathioprine, 6-MP, cyclosporin), and metronidazole.
• Nutritional status and disease occurrence across all age groups, especially in children and adolescents, require careful consideration.

Purpose of the Study:

• To review current and emerging treatment strategies for inflammatory bowel disease (IBD).
• To highlight the importance of nutritional support and age-specific management in IBD.
• To discuss the potential of novel therapeutic agents in IBD management.

Main Methods:

• Review of established and experimental treatments for ulcerative colitis and Crohn's disease.
• Discussion of pathogenetic mechanisms guiding therapeutic development.
• Exploration of new agents like immunoglobulin G, eicosapentaenoic acid, and 5-lipoxygenase inhibitors.

Main Results:

• Standard treatments include corticosteroids, sulphasalazine, immunosuppressants, and metronidazole.
• Nutritional status and age-specific considerations are crucial in IBD management.
• Emerging therapies show promise for more effective and safer IBD treatment.

Conclusions:

• While the exact causes of IBD are unknown, current treatments target underlying mechanisms.
• Ongoing research into novel agents like immunoglobulin G and eicosapentaenoic acid offers hope for improved IBD therapies.
• A comprehensive approach, including nutritional support and tailored management, is essential for patients with inflammatory bowel disease.